Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results

Crinetics Pharmaceuticals, Inc.

Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.
Oral presentation of long-term PATHFNDR-1 open-label extension data for paltusotine in acromegaly, showing durable biochemical and symptom control.
Phase 2 open-label trial results for atumelnant in congenital adrenal hyperplasia featured as oral presentation; data on adrenal volume and androgen reductions.
Early-stage pipeline data on CRN12755, a TSHR antagonist for Graves' hyperthyroidism and orbitopathy, also to be presented.
PALSONIFY conditionally approved as trade name by FDA; atumelnant Phase 2 interim results show rapid reductions in androstenedione and 17-hydroxyprogesterone.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.